Theme

Ribociclib Plus Fulvestrant Extends Survival Without Sacrificing Quality of Life

Source
Source: Health-related quality-of-life analyses from the MONALEESA-3 Phase III trial, assessing ribociclib plus fulvestrant for advanced breast cancer (Fasching et al., 2020).

MONALEESA-3 Trial Context: Patient-Reported Outcomes (PROs) definitively prove that the targeted therapy's ability to significantly extend progression-free and overall survival does not come at the cost of the patient's daily quality of life in advanced breast cancer.

Global Health Status

HR = 0.81

Adding Ribociclib to treatment noticeably delayed a 10% deterioration in overall patient well-being compared to placebo.

Maintained Health

33% vs 34%

Patients experiencing definitive 10% GHS deterioration (Ribociclib vs Placebo), demonstrating zero added quality-of-life toxicity.

Clinical Recommendation

For postmenopausal women with HR+/HER2- advanced breast cancer, providers can confidently recommend this regimen. It delivers a dual clinical benefit: improving survival while maintaining—and in some symptoms, improving—health-related quality of life.

Delayed Pain Progression

Median Time to Deterioration in Pain Severity (Months) — HR = 0.77

Early Symptom Relief

Reduction in Overall Pain Score Observed at 8 Weeks of Treatment

Quality of Life Symptom Management Overview

Clinical Metric Ribociclib + Fulvestrant Placebo + Fulvestrant Outcome Context
Definitive 10% GHS Deterioration 33% 34% HR = 0.81 (Deterioration safely delayed)
Median Time to Pain Deterioration 42 Months 35 Months HR = 0.77 (Significant delay in worsening pain)
Early Pain Reduction (8 Weeks) -4.0 points -3.6 points Maintained relief throughout treatment
AbbreviationsQuick
BPI-SF: Brief Pain Inventory-Short form; C: cycle; CI: confidence interval; D: day; EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire; EOT: end of treatment; FUL: fulvestrant; GHS: global health status; HER2: human epidermal growth factor receptor-negative; HR: hazard ratio; HR+: hormone receptor-positive; HRQOL: health-related quality of life; LSM: least squares mean; NE: not estimable; OS: overall survival; PBO: placebo; PFS: progression-free survival; PRO: patient-reported outcome; QOL: quality of life; RIB: ribociclib; SD: standard deviation; SEM: standard error of the mean; TTD: time to definitive deterioration.
Bibliography4
  1. Fasching PA, Beck JT, Chan A, et al. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 2020;54:148-154. (DOI: 10.1016/j.breast.2020.09.008 | link)
  2. Rugo HS, Dieras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 2018;29(4):888-894. (DOI: 10.1093/annonc/mdy012 | link)
  3. Goetz MP, Johnston S, Martin M, et al. Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer. SABCS annual meeting; 2018. Abstract P6-16-01.
  4. Verma S, O'Shaughnessy J, Burris HA, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2. Breast Cancer Res Treat 2018;170(3):535-545. (DOI: 10.1007/s10549-017-4658-x | link)